PHARMA DEALS DURING OCTOBER 2014

(Part 3 out of 3)

by Roger Davies

This table lists all the major pharma collaborations, acquisitions and mergers agreed during October 2014

Licensor acquired / licensee acquirer	Deal type	Product / technology	Headline ($m)
Becton Dickinson/CareFusion	Company acquisition	Medical equipment builds US sales base	12,200
Auxilium/Endo	Company acquisition	Urology and orthopaedic products including alprostadil for ED	2,600
NewLink Genetics/Genentech	Collaboration and licence	For development of NLG919 and next generation IDO pathway inhibitors	1,150
Sutro Biopharma/Celgene	Licence plus option to acquire Sutro	For development of multispecific antibodies and antibody drug conjugates (ADCs)	1,000
Aduro BioTech/J&J	Expansion of collaboration	Lung cancer immunotherapies including ADU 214	847
Lineage Therapeutics/Impax Laboratories	Company acquisition	Includes generic and branded products such albendazole and epinephrine	700
Actavis/Durata Therapeutics	Merger with Actavis subsidiary	Brings Dalvance a recently approved  novel antibiotic for acute skin structure infections	675
Acorda Therapeutics/Civitas Therapeutics	Company acquisition	Includes CVT 301 in P3 for Parkinson's as well as pulmonary delivery technology	525
F-star Alpha/BMS	Option to acquire F-star Alpha	Includes FS102 a P1 ready treatment for HER2 positive patients with breast /    gastric cancer	475
CureTech/Medivation	Exclusive global licence	For pidilizumab (CT-011), an immune modulatory anti-PD-1 monoclonal antibody	335
Forendo Pharma/Apricus Biosciences	Licence [A]	Fispemifene a selective oestrogen modulator in P2 for secondary hypogonadism	318
Novartis/CSL	Asset purchase	Influenza vaccines	275
Five Prime/GSK	Expansion of collaboration	Identifying new agents in asthma and COPD	196
Bavarian Nordic/J&J	Licence and supply	For multivalent MVA-BN Filovirus vaccine	187
Lexicon Pharmaceuticals/Ipsen	Licence [B]	Telotristat etiprate in P3 for carcinoid syndrome	145
Brabant Pharma/Zogenix	Acquisition	Includes fenfluramine for orphan I indication of Dravet syndrome	130
TesoRx Pharma/Aspen	Licence [C]	For TSX 002 an unmodified oral   testosterone replacement	95
Oxford BioMedica/Novartis	Expansion of collaboration	Lentiviral vectors expressing CTL019 CAR-T therapy for leukaemia	90
Heidelberg Pharma/Roche	Licence with options to targets	Development of ADCs based on coupling α-amantin to antibodies	66

All deals are worldwide unless otherwise noted.
A: US only
B: Outside N America and Japan
C: Excluding US EU Japan, China and the Middle East

Fuente: PMLiVE

Haciendo click en cada uno de los links siguientes, 

accederán a los Contenidos de nuestros 

TALLERES DE CAPACITACIÓN IN COMPANY A MEDIDA:

(translator on page)

¿Cómo INCORPORAR y APLICAR Modelos de
PENSAMIENTO ESTRATÉGICO?
(aplicado al Sector Salud y Farma, con resolución de casos reales en tiempo real)

http://msg-latam-meic.blogspot.com.ar/2014/06/capacitacion-in-company-programa_6246.html

¿Cómo GERENCIAR EFICAZMENTE a partir del

MANAGEMENT ESTRATÉGICO?

(aplicado al Sector Salud y Farma, con resolución de casos reales en tiempo real)

http://msg-latam-meic.blogspot.com.ar/2014/06/capacitacion-in-company-programa_3.html

¿Cómo GERENCIAR PROCESOS DE CAMBIO

y no sufrir en el intento?

(aplicado al Sector Salud y Farma, con resolución de casos reales en tiempo real)

http://msg-latam-meic.blogspot.com.ar/2014/06/capacitacion-in-company-programa.html

¿Cómo IMPLEMENTAR ESTRATEGIAS EFECTIVAS?

Recetas para Escenarios Turbulentos

(aplicado al Sector Salud y Farma, con resolución de casos reales en tiempo real)

http://msg-latam-meic.blogspot.com.ar/2014/06/capacitacion-in-company-taller-de.html

Consultas al mail: msg.latam@gmail.com

ó al TE: +5411-3532-0510